Review Article

Treatment for Recurrent Ovarian Cancer—At First Relapse

Table 4

Study result for platinum resistant recurrent ovarian cancer (single agent).

PLDGEMTopotecanPLD versusPLO versus GEM
Topotecan

Dose50 mg/ m 2 /4w1 g/ m 2 1.5 mg/ m 2 d1–5/3w50 mg/ m 2 /4w50 mg/ m 2 /4w

d1.8.15/4w(1 mg/ m 2 /3w)1.5 mg/ m 2 for 5 d/3w19/d1.8/3w
AuthorGordon et al. [31]Markman [11] Bookman et al. [15]O’Malley et al. [13]Mutch et al. [14]
(Rodriguez et al. [36])
Number of patients8251112 (37)130 versus 12496 versus 99
Response rate
CR + PR (%)18.31612.4 (22 )12.3 versus 6.58.3 versus 6.1
   + SD (%)66.1NANA(44)40 versus 49.246.9 versus 60.6
Most frequent
Adverse effectPPEneutropenianeutropeniaPPE/neutropeniafatigue/fatigue
PFS (weeks)171612.1 (18)9.1 versus 13.612.4 versus 14.4
OS (weeks)15 (months)47 (NA)35.6 versus 41.350.8 versus 54

PPE: palmar-plantar erythrodysesthesia.